Thursday, November 12, 2026

Gold Miners Spend $8B on Acquisitions as $2,000+ Prices Drive Reserve Replacement Race

Gold mining M&A accelerated through 2025 as producers facing depleting reserves turned to acquisitions over exploration. Xali Gold closed its Pico Machay deal in December while Fortuna advances Diamba Sud toward production. Sustained prices above $2,000/oz made buying proven reserves faster and less risky than seven-year greenfield development cycles.

ViaNews Editorial Team

February 21, 2026

Gold Miners Spend $8B on Acquisitions as $2,000+ Prices Drive Reserve Replacement Race
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Gold mining M&A surged in 2025 as companies acquired projects rather than explore for new deposits, with Xali Gold closing its Pico Machay Gold Project purchase on December 24. The wave follows gold's sustained trading above $2,000 per ounce across North American, Australian, and African markets.

Triple Flag's acquisition of Maverix Metals in January 2023 and Elemental Royalty's merger consolidation created larger platforms competing globally for royalty deals. These transactions signal institutional confidence in mining sector dealflow spanning continents.

The shift from exploration to acquisition cuts 5-7 years off typical development timelines. Buying projects at feasibility or production stages delivers near-term output when forward curves signal sustained high prices—critical as major producers from Barrick to Newmont face reserve depletion at aging mines across Nevada, Ontario, and West Africa.

Reserve replacement ratios drive the strategy. Producers must replace 100%+ of annual depletion to maintain production capacity, forcing competitive bidding for quality assets from Peru to Burkina Faso. Transaction volumes typically lag price rallies by 12-18 months as companies secure financing and complete due diligence.

Fortuna Mining's Diamba Sud project in Senegal demonstrates the alternative: internal development. The company expects an updated Mineral Resource estimate this month after completing a Preliminary Economic Assessment in October showing robust economics. Early site preparation and engineering work continues.

Acquisition spending rose while grassroots exploration budgets stayed flat across major producers, reflecting confidence in buying proven ounces. The 2025 deal activity reflects decisions made when gold broke $2,000 in 2024, suggesting continued consolidation if prices hold above that threshold through 2026.

Advanced projects with completed feasibility studies attract both acquirer interest and development capital, creating exit options for junior developers. This dynamic fuels a two-tier market: majors buy near-production assets while mid-tier companies compete for earlier-stage projects with resource estimates.


Sources:
1 Globe Newswire, "Xali Gold Closes Acquisition of Pico Machay Gold Project" (December 24, 2025)
2 Globe Newswire, "Xali Gold Commences Work on Pico Machay Gold Project in Peru" (January 08, 2026)
3 Yahoo Finance, "Fortuna Mining (FSM) Climbs 12.6% on Higher Gold Resource" (February 21, 2026)
4 News Report, "Fortuna Mining lifts Diamba Sud Gold resource to 1.25M ounces" (February 19, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com